Primaxin IV is a brand name of Imipenem and cilastatin sodium, a prescription medicine. The FDA NDC Directory lists 1 Primaxin IV product in 1 strength and form.

Who makes Primaxin IV?

Merck holds the FDA application for Primaxin IV (NDA050587, approved November 26, 1985).

Is there a generic or store brand of Primaxin IV?

Other products of Imipenem and cilastatin sodium are listed with the FDA, but none in exactly the same strength and form as a Primaxin IV product.

Primaxin IV (Imipenem and cilastatin sodium): maker, FDA approval and generic versions

Official data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the NDC Directory, Drugs@FDA, the official labels and recall reports; pharmacy costs come from the Centers for Medicare & Medicaid Services (CMS). Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or switch any medicine, including a switch between a brand and a generic.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Primaxin IV?: Primaxin IV is a brand name of Imipenem and cilastatin sodium, a prescription medicine. The FDA NDC Directory lists 1 Primaxin IV product in 1 strength and form.
Who makes Primaxin IV?: Merck holds the FDA application for Primaxin IV (NDA050587, approved November 26, 1985).
Is there a generic or store brand of Primaxin IV?: Other products of Imipenem and cilastatin sodium are listed with the FDA, but none in exactly the same strength and form as a Primaxin IV product.
Has Primaxin IV been recalled?: No recall linked to Primaxin IV products (by their NDC code or label) appears in the FDA enforcement reports we use.

What Primaxin IV is

Each Primaxin IV product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.

Imipenem and cilastatin sodium · prescription medicine

Strength and form	Product names	Same medicine, other names	Label
cilastatin sodium 500 mg/100 mL · imipenem 500 mg/100 mL injection, powder, for solution (intravenous)	Primaxin IV	None listed	—

Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Imipenem and cilastatin sodium →

FDA approval

NDA: New Drug Application: how a new (usually brand-name) medicine is approved.

FDA applications of Primaxin IV products (Drugs@FDA)
Application	Holder	First approved	Products
NDA050587	Merck	November 26, 1985	1

Companies that list Primaxin IV

The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Primaxin IV products.

Merck Sharp & Dohme LLC1 product

Recalls

No recall linked to Primaxin IV products (by their NDC code or label) appears in the FDA enforcement reports.

Sources

NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026

Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.

Report an error → · Information for medicine makers

Primaxin IV